← Russell 3000 cross-section

GILD GILEAD SCIENCES, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$184.2bn
Revenue TTM
$30.5bn
Net income TTM
$-3.2bn
Free cash flow
$12.9bn
Composite score
51.8
Sector rank
#67

Valuation

P / E
EV / EBITDA
EV / sales
6.9
FCF yield
7.03%
Earnings yield vs 10-yr
-6.49pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-10.6%
EBITDA margin
-7.0%
ROE
-27.4%
ROIC
-6.6%
Revenue growth
5.5%

Insider activity, last 90 days

Net open-market
$-15.02m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the collaboration agreement, Arcellx was eligible to receive performance-based development and regulatory milestone payments, with further commercial milestone payments, profit split payments on co-promoted products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opted in to co-promote the future products. We will retain commercialization rights and pay Lakefront royalties of 20 % to 23 % on net sales of gamgertamig products. …GILEAD SCIENCES, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →